Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Gagan Singh, MD

Description

Summary

To evaluate the feasibility and safety of the Millipede Transcatheter Annuloplasty Ring System in subjects with functional mitral regurgitation

Official Title

A Study to Evaluate the Feasibility and Safety of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation: (Millipede Feasibility Study)

Details

The Millipede Feasibility Study is a prospective, open-label, single-arm study to assess the safety and feasibility/performance of the Millipede Transcatheter Annuloplasty Ring System in subjects with functional mitral regurgitation. The study will include subjects with functional mitral regurgitation classified as moderate to severe (3+) or severe (4+) that are symptomatic (NYHA Class II-IV) despite guideline directed medical therapy in whom the local hearth team determines that surgery is not an option for mitral valve repair. Clinical follow-up will be required in hospital, 30 days, 90 days, 6 months, 12 months, and then annually through 5 years post-procedure. Subjects who have any part of the Millipede Transcatheter Annuloplasty Ring System introduced into the body but who do not end up with an implant will be followed through 30 days.

Keywords

Mitral Regurgitation Functional Mitral Valve Disease Cardiovascular Diseases Functional Mitral Regurgitation Mitral Repair Mitral Valve Insufficiency Millipede Transcatheter Annuloplasty Ring System (Millipede System) Mitral Valve Repair

Eligibility

You can join if…

Open to people ages 18 years and up

  • Subject is 18 years of age or older
  • Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed
  • Subject has moderate to severe (3+) or severe (4+) functional mitral regurgitation confirmed by echocardiography core lab
  • Subject is symptomatic (NYHA Class II-IV) despite guideline directed medical therapy, including CRT if indicated
  • The local site heart team concurs that mitral valve surgery will not be offered as a first-line treatment option
  • Subject is a candidate for annuloplasty based on the criteria below as assessed by the investigative site (and confirmed by the Case Review Committee [CRC]):

Left Ventricular Ejection Fraction (LVEF) ≥ 25% Left Ventricular End Diastolic Diameter (LVEDD) ≤ 65 mm Coaptation distance (i.e. tenting height) < 10 mm Absence of posterior wall aneurysm

You CAN'T join if...

  • Subject has severe calcification of the mitral annulus or leaflets or other anatomic features that make the subject unsuitable for annuloplasty with the Millipede System in the judgment of the treating physician or subject does not have suitable mitral annular diameter (determined by CT) as per the Instructions for Use
  • Transfemoral venous and transseptal access determined not to be feasible
  • Subject is on the waiting list for a transplant or has had a prior heart transplant
  • Subject has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 30 days prior to study enrollment
  • Subject has had any percutaneous coronary, carotid, or other endovascular intervention within 30 days prior to study enrollment
  • Subject has had carotid surgery within 30 days prior to study enrollment
  • Subject has had any open coronary or vascular surgery (other than carotid surgery) within 3 months prior to study enrollment
  • Subject has had a cardiac resynchronization therapy (CRT) device implantation within 3 months prior to study enrollment
  • Subject has untreated clinically significant coronary artery disease requiring revascularization
  • Any planned cardiac surgery within the next 12 months
  • Need for emergent or urgent surgery for any reason
  • Subject has severe aortic valve stenosis and/or aortic valve regurgitation
  • Subject has physical evidence of right-sided congestive heart failure (CHF) with echocardiographic evidence of moderate or severe right ventricular dysfunction and/or severe tricuspid valve regurgitation
  • Subject has the presence of prosthetic heart valve in any position
  • Subject has renal insufficiency (eGFR <20mL/min) and is not on dialysis
  • Subject has a life expectancy less than 12 months
  • Subjects in whom trans-esophageal echocardiography-Doppler assessment is contraindicated or in which mitral regurgitation is not measurable by Transthoracic Echocardiography (TTE)
  • Subject has a prior history of atrial septal defect (ASD) closure or patient foramen ovale (PFO) closure
  • Subject has fixed pulmonary artery systolic pressure > 70 mmHG
  • Subject has known hypersensitivity or contraindication to protocol required procedural or post procedural medication (e.g., anticoagulation therapy) or hypersensitivity to nickel or titanium
  • Subject has known hypersensitivity to contrast that cannot be adequately premedicated
  • Female subject who is breast feeding or is pregnant and planning to become pregnant within the study period
  • Subject is participating in another investigational drug or device study that has not reached its primary endpoint or subject intends to participate in another investigational device clinical trial within 12 months after index procedure
  • Subject has a history of endocarditis within 6 months of index procedure or evidence of an active systemic infection or sepsis
  • Subject has oxygen-dependent chronic obstructive pulmonary disease
  • Subject has documented severe liver disease
  • Subject has Hgb <8 g/dL, platelet count <50,000 cells/mm3 or >700,000 cells/mm3, or white blood cell count <1,000 cells/mm3
  • Subject has any evidence of intracardiac thrombus

Locations

  • University of California, Davis Medical Center accepting new patients
    Sacramento California 95817 United States
  • Los Robles Hospital & Medical Center accepting new patients
    Thousand Oaks California 91360 United States

Lead Scientist at UC Davis

  • Gagan Singh, MD
    Associate Professor, Cardiovascular Medicine. Authored (or co-authored) 90 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Boston Scientific Corporation
Links
Sign up for this study
ID
NCT04147884
Study Type
Interventional
Last Updated